The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy
Open accessAbstract
The prevalence of antithyroid peroxidase antibodies (ATPO) and/or of thyroid dysfunction was studied in 422 patients with chronic viral hepatitis C, B, and D. Baseline results were compared with those during and 6 months after interferon alfa (IFN-α) therapy. The overall prevalence of ATPO among untreated patients was 14.1%, with no significant differences between chronic hepatitis C, B, or D, as well as between males and females. However, high ATPO titers (≥ 18 IU/mL) clustered significantly among females (8.7% vs. 3.4%; P = .022), especially those with chronic hepatitis C (11.2% vs. 3.6%; P = .036). Before treatment, 3.7% of the patients had thyroid dysfunction, mostly hypothyroidism (3.5%), the latter increasing to 14.3% among patients with ATPO titers ≥ 18 IU/mL. IFN-α treatment significantly increased overall thyroid dysfunction (9.7%; P = .001) and hypothyroidism (7.8%; P = .01), particularly among patients with high baseline ATPO (38.5%; P = .0002). Six months after stopping IFN-α treatment, the prevalence of thyroid dysfunction was 8.0%, still significantly higher than at baseline. By multivariate analysis, the only predictor positively associated with pre- or on-treatment hypothyroidism was the baseline titer of the ATPO antibodies (relative risk [RR], 3.0 and 3.8 per each log titer increase, respectively). In conclusion, patients with chronic viral hepatitis on IFN-α treatment exhibit an almost threefold increase of baseline thyroid dysfunction, persisting long after the end of therapy. High ATPO titers, clustering among females, particularly those with hepatitis C, represent the only predictor of pre- and on-treatment hypothyroidism by multivariate analysis. Patients with chronic viral hepatitis, especially females, should be tested for ATPO and thyroid function and monitored during and posttreatment for free thyroxin (FT4) and thyroid- stimulating hormone (TSH) levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical associations between thyroid and liver diseases
HUANG, M., & LIAW, Y. (1995) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.1995.tb01106.x · Cited by 186
Cited by
Prognostic Significance of Autoimmunity during Treatment of Melanoma with Interferon
Gogas, H., Ioannovich, J., Dafni, U., Stavropoulou-Giokas, C., Frangia, K., Tsoutsos, D., Panagiotou, P., Polyzos, A., Papadopoulos, O., Stratigos, A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053007 · Cited by 566
Prognostic significance of autoimmunity during treatment of melanoma with interferon
Krauze, M. T., Tarhini, A., Gogas, H., & Kirkwood, J. M. (2011) · Seminars in Immunopathology · doi:10.1007/s00281-011-0247-y · Cited by 507
The relationship between the thyroid gland and the liver
MALIK, R. (2002) · QJM · doi:10.1093/qjmed/95.9.559 · Cited by 413
Zignego, A. L., Ferri, C., Pileri, S. A., Caini, P., & Bianchi, F. B. (2007) · Digestive and Liver Disease · doi:10.1016/j.dld.2006.06.008 · Cited by 262
Side effects of therapy for chronic hepatitis C
Russo, M. W., & Fried, M. W. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00394-9 · Cited by 261
Metadata
- Authors
- Deutsch, M., Dourakis, S., Manesis, E. K., Gioustozi, A., Hess, G., Horsch, A., & Hadziyannis, S.
- Venue
- Hepatology
- Published
- 1997-07
- Volume
- 26
- Issue
- 1
- Pages
- 206-210
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2064870615
- Cited by
- 182
- References
- 1
- FWCI
- 3.98
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.